Ceptaris Therapeutics Inc., a privately held, specialty
pharmaceutical company, is developing a proprietary formulation
of mechlorethamine gel for the treatment of early stage (stages
I-IIA) mycosis fungoides, a type of Cutaneous T-Cell Lymphoma.
Based upon results of a recently completed trial, Ceptaris submitted a new drug application (NDA) with the Food and Drug
Administration (FDA) in 2011. If approved, Ceptaris'
investigational drug would be the first topical mechlorethamine
product available to treat the signs and symptoms of this
Ceptaris has augmented its management team with the addition of a
number of experienced pharmaceutical executives as it approaches
regulatory filing and potential commercialization of mechlorethamine gel.